Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Javier Hasse

MYSTERIOUS: Exclusive global psychedelics company silo wellness acquires dyscovry science including access to its gov collaborations - What They Never Told You

According to information procured exclusively by Benzinga ahead of an official announcement, global psychedelics company Silo Wellness Inc. (OTCQB:SILFF) (CSE:SILO) (FSE: 3K7A) is acquiring Dyscovry Science Ltd., a Toronto-based biotech company focused on biosynthetic manufacturing of psilocybin and its derivatives targeting irritable bowel syndrome.

Per terms of the deal, Silo will acquire 100% of the issued and outstanding shares of Dyscovry in exchange for 12,762,325 common shares in the capital of Silo, representing a total of 49% of the issued shares post-closing of the transaction. The payment shares issued to Dyscovry will be subject to restrictions on resale for a period of 36 months from the closing of the acquisition and will be released on a schedule consistent with the release schedule for an “emerging issuer” prescribed by section 4.3 of National Policy 46-201- Escrow for Initial Public Offerings.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.